substack.com

AGL Q1 Follow Up: “At Least” $125 million

2026-05-11 · 17:26 UTC ·Lake Cornelia Commentary ·3 min read

Brief

AGL — following a May 11, 2026 post‑earnings investor relations call — clarified its 2026 cash guidance is “at least $125 million” (versus $376M cash at end‑2025), which, together with the Q1 print and further analysis, left the author incrementally bullish about upside to EBITDA and the company’s balance‑sheet conservatism. The note presents simple math: ~18 million diluted shares, 2026E net cash ~$105M and a TEV of $885M, while the stock trades at under 0.2x TEV/Revenue and 2.4x Medical Margin — levels the author says reflect an outsized market fear of insolvency. The memo also highlights a presumed $250M prior‑year claims outflow that may be overstated, and corporate incentives (CEO grant vesting at $50/100/150 after grants made when shares were < $30). The author contends shares must rally to at least $150+ (on a longer path to $250) before being fairly priced as a going concern.

Why it matters

On May 11, 2026 Lake Cornelia reported that a post‑Q1 investor relations call clarified AGL’s 2026 cash guidance is “at least $125 million” (the company had $376M cash at 12/31/2025), a point that increased the author’s bullishness.

Key details

  • Author’s valuation math: ~18 million diluted shares, 2026E net cash of $105 million and a total enterprise value (TEV) of $885 million; the stock trades below 0.2x TEV/Revenue and at 2.4x Medical Margin, implying the market prices material insolvency risk.
  • The writeup argues AGL should rerate if management’s conservative guidance and upside to EBITDA play out — the author sees shares needing to reach at least $150+ (on a path the author labels toward $250) before the company is fairly priced as a going concern.
  • Key corporate detail: presumed prior‑year claims created a $250 million negative outflow assumption that the Q1 print, the IR call, and further analysis suggest could have upside (i.e., downside risk to cash is overstated); new CEO’s equity vests at $50/100/150 (granted when shares were < $30).
Cleaned source text

The Road to $250 per share (stock is ~$53)

͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­͏ ­

Forwarded this email? Subscribe here for more

AGL Q1 Follow Up: “At Least” $125 million

Lake Cornelia Commentary

May 11| | | ∙| | Preview

READ IN APP

May 11th, 2026

Lake Cornelia Research Management, Inc.

Note: Please read the disclaimer and risk disclosures at the end of the memo before preceding.

We had a follow-up call post earnings with IR. This was our first call with the company and was extremely helpful. Into Q1, we argued that two things needed to be demonstrated: (1) 2026 guidance was sandbagged and (2) there was potential upside to the $250 million presumed negative outflow from prior year claims. The combination of the Q1 print, our management call and further analysis leave us incrementally bullish on both fronts.

Please refer to our prior notes for a full explanation of the AGL story. The balance sheet was a huge focus for us, principally the year 2026E cash guidance of $125 million (down from $376 million at the end of 2025). We failed to appreciate that the actual guidance was “at least $125 million” and were delighted to understand the plethora of examples of potential upsides to EBITDA and the conservatism imbedded in the cash balance guide.

The simple math on AGL is ~18 million diluted shares, 2026E net cash of $105 million and a current TEV of $885 million. At current levels, we believe the market is still pricing in a material risk of insolvency. Trading at under 0.2x TEV/Revenue and 2.4x Medical Margin, with management demonstrating a funded growth story with significant duration and runway, we see shares needing to rally to at least $150+ per share (still sub 0.5x TEV/Revenue) before we can even begin to feel that its priced fairly as a going concern. We further note that the new CEO’s stock grant vests in 1/3rd each at $50 / 100 / 150 per share – which was granted when AGL shares were under $30. At the end of March, shares bottomed under $8 per share driven lower by the technicals from the 25 / 1 reverse stock split...

Continue reading this post for free in the Substack app

Claim my free post

Or upgrade your subscription. Upgrade to paid

Like

Comment

Restack

© 2026 Judd Arnold

548 Market Street PMB 72296, San Francisco, CA 94104